Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/17/2/217/392018/mdj048.pdf
Reference37 articles.
1. Aromatase inhibitors in breast cancer;Lønning;Endocr Relat Cancer,2004
2. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial;Baum;Lancet,2002
3. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer;Goss;N Engl J Med,2003
4. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer;Coombes;N Engl J Med,2004
5. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004;Winer;J Clin Oncol,2005
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost–utility analyses of drug therapies in breast cancer: a systematic review;Breast Cancer Research and Treatment;2016-08-30
2. Aromatase inhibitors;Meyler's Side Effects of Drugs;2016
3. Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women;Recent Advances in Medicinal Chemistry;2014
4. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved;Endocrine-Related Cancer;2013-04-26
5. Genetic Testing in Combination with Preventive Donepezil Treatment for Patients with Amnestic Mild Cognitive Impairment;Molecular Diagnosis & Therapy;2012-11-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3